Evaluating the addition of Venetoclax for treating chronic lymphocytic leukemia.
Official title: Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Funded at Kansas City VA Medical Center · NIH-10801637 · Data updated 2026-11-12
This study is looking at whether adding Venetoclax to the treatment for people with chronic lymphocytic leukemia who are already doing well on another medication can make the treatment work better and cause fewer side effects, all while helping improve your quality of life.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Kansas City VA Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project start | February 1, 2025 |
| Project end | January 31, 2030 |
| Funding year | 2025 |
| NIH project number | 1I01CX002685-01A1 |
| Project ID | NIH-10801637 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are veterans diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma who are currently being treated with BTKi and are responding positively.
✕Less likely to help
Patients who are not veterans or those who have not been diagnosed with CLL/SLL may not benefit from this research.
What this research studies
This research investigates the effects of adding Venetoclax to the treatment regimen of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) who are already responding to Bruton’s tyrosine kinase inhibitors (BTKi). The study aims to determine if this combination therapy can enhance treatment effectiveness while reducing long-term side effects. Patients will receive both medications for one year, after which both will be discontinued to assess the depth of response and overall patient experience. The focus is on improving quality of life and minimizing toxicities associated with ongoing treatment.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes and quality of life for patients with CLL/SLL.
How similar studies have gone: Previous research has shown promising results with combination therapies in similar contexts, indicating potential for success in this approach.
Where this research is happening
-
Kansas City VA Medical Center
Kansas City, United States Active
Researchers
- Principal investigator: Kambhampati, Suman — Kansas City VA Medical Center
- Study coordinator: Kambhampati, Suman
Related research
Other NIH-funded projects on the same topics.
-
Bone marrow grafting and cellular therapies for leukemia and lymphoma
A program at Stanford aims to improve bone marrow transplantation and newer cellular therapies to treat blood cancers like leukemia and lymphoma.
-
Tracing how chronic lymphocytic leukemia can change into Richter’s syndrome
A physician-scientist is studying why CLL sometimes changes into Richter’s syndrome and how this transition happens at the genetic level, with the goal of better outcomes for people living with CLL.
-
Paradigm shift in managing untreated chronic lymphocytic leukemia in older adults
A Mayo Clinic doctor is leading a national collaboration to advance new frontline treatments for older adults with chronic lymphocytic leukemia.
-
AVO: a new triplet therapy for untreated high-risk CLL
A new, time-limited combination therapy (acalabrutinib, venetoclax, and obinutuzumab) is being tested for people with newly diagnosed high-risk CLL to see how well it works and how safe it is.
-
Rewiring cancer pathways to trigger death in chronic lymphocytic leukemia
A Stanford-led study aims to use a new class of small molecules to flip cancer-driving signals so CLL cells die, offering hope for patients who have exhausted other therapies.
-
METTL3's role in driving a stubborn form of chronic lymphocytic leukemia
A cancer-related study looks at how METTL3 helps a common leukemia (CLL) grow and resist treatment, with the goal of finding better therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.